Positive data for Roche multiple sclerosis injection
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
CHL is strengthening its play in the fast-growing beauty and personal care sector
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
The company plans to add 1700 beds by FY27 through the organic route
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
Subscribe To Our Newsletter & Stay Updated